Table 3.

Serum levels of C3a and C5a and the concentration of MPO+MP, and C3a-positive and C5a-positive MPO+MP in plasma of patients with AAV as well as controls.

VariablesTotal AAV, n = 46Active AAV, n = 23Inactive AAV, n = 23Controls, n = 23
MPO+MP, median (range) or mean ± SD76.0 (7.2–613.0)**80.0 (23.0–613.0)***72.6 (7.2–250.2)**46.6 ± 23.2
C3a+ MPO+MP, mean ± SD110.8 ± 49.7**120.2 ± 51.3*** ‡101.4 ± 47.3*62.2 ± 32.1
C3a serum, ng/ml, mean ± SD1887 ± 744.11738 ± 658.82036 ± 807.62066 ± 837.9
C5a+ MPO+MP, mean ± SD83.7 ± 71.8**92.7 ± 57.6** ‡74.7 ± 44.7**29.9 ± 15.0
C5a serum, ng/ml, mean ± SD22.6 ± 10.823.3 ± 10.521.9 ± 11.320.7 ± 7.8

  • Patients vs controls:

  • ↵* p < 0.05;

  • ↵** p < 0.01;

  • ↵*** p < 0.001.

  • ↵‡ Active versus inactive patients. MPO+MP: myeloperoxidase-positive microparticles; AAV: antineutrophil cytoplasmic antibody–associated vasculitis.